Ask AI
ProCE Banner Activity

A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer

Podcast Episodes

This episode features Dr Rachel Grisham and Dr Kathleen Moore discussing the historical challenges associated with treating low-grade serous ovarian cancer and the recent transformational approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC.

Released: November 06, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Verastem, Inc.

Verastem, Inc.

Faculty Disclosure

Primary Author

Rachel Grisham, MD: consultant/advisor/speaker: AstraZeneca, GSK, Incyclix, Incyte, SpringWorks; other financial or material support: Verastem.

Kathleen N. Moore, MD, MS, FASCO: consultant/advisor/speaker: Aadi, AbbVie, AstraZeneca, BioNTech, Blueprint, Caris, Corcept, Daiichi Sankyo, Duality, Eisai, Genentech/Roche, GSK, Immunogen, Janssen, Loxo-Lilly, Merck, Mersana, Novartis, Regeneron, Schrödinger, Takeda, Verastem, Whitehawk, Zentalis.